{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunoglobulin+A+Nephropathy&page=2",
    "query": {
      "condition": "Immunoglobulin A Nephropathy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunoglobulin+A+Nephropathy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T08:15:36.916Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07146906",
      "title": "A Study to Assess the Effects of Zigakibart on IgA Nephropathy.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immunoglobulin A Nephropathy (IgAN)"
      ],
      "interventions": [
        {
          "name": "zigakibart",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 32,
      "start_date": "2026-03-26",
      "completion_date": "2030-10-18",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-05-22T08:15:36.916Z",
      "location_count": 3,
      "location_summary": "Denver, Colorado • Acworth, Georgia • Edina, Minnesota",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Acworth",
          "state": "Georgia"
        },
        {
          "city": "Edina",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07146906"
    },
    {
      "nct_id": "NCT03926117",
      "title": "Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Diseases",
        "Inflammation"
      ],
      "interventions": [
        {
          "name": "Ziltivekimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 264,
      "start_date": "2019-06-03",
      "completion_date": "2020-06-26",
      "has_results": true,
      "last_update_posted_date": "2025-12-31",
      "last_synced_at": "2026-05-22T08:15:36.916Z",
      "location_count": 49,
      "location_summary": "Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 40 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Lynwood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03926117"
    },
    {
      "nct_id": "NCT06983028",
      "title": "Atacicept in Multiple Glomerular Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "pMN",
        "IgAN",
        "Nephrotic Syndrome",
        "MCD",
        "FSGS"
      ],
      "interventions": [
        {
          "name": "Atacicept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vera Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2025-07-07",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-05-22T08:15:36.916Z",
      "location_count": 1,
      "location_summary": "Brisbane, California",
      "locations": [
        {
          "city": "Brisbane",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06983028"
    },
    {
      "nct_id": "NCT05027074",
      "title": "Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "End-Stage Renal Disease",
        "End-Stage Kidney Disease",
        "Kidney Failure, Chronic"
      ],
      "interventions": [
        {
          "name": "MK-2060",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 506,
      "start_date": "2021-09-17",
      "completion_date": "2025-02-13",
      "has_results": true,
      "last_update_posted_date": "2026-02-11",
      "last_synced_at": "2026-05-22T08:15:36.916Z",
      "location_count": 77,
      "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05027074"
    },
    {
      "nct_id": "NCT03454451",
      "title": "CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Renal Cell Cancer",
        "Colorectal Cancer",
        "Triple Negative Breast Cancer",
        "Cervical Cancer",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Endometrial Cancer",
        "Sarcoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Bladder Cancer",
        "Metastatic Castration Resistant Prostate Cancer",
        "Non-hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "CPI-006",
          "type": "DRUG"
        },
        {
          "name": "CPI-006 + ciforadenant",
          "type": "DRUG"
        },
        {
          "name": "CPI-006 + pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corvus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 117,
      "start_date": "2018-04-25",
      "completion_date": "2023-02-19",
      "has_results": false,
      "last_update_posted_date": "2023-12-21",
      "last_synced_at": "2026-05-22T08:15:36.916Z",
      "location_count": 22,
      "location_summary": "Tucson, Arizona • Duarte, California • San Francisco, California + 18 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03454451"
    },
    {
      "nct_id": "NCT06797518",
      "title": "Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glomerulonephritis, IGA",
        "Immunoglobulin A Nephropathy"
      ],
      "interventions": [
        {
          "name": "Iptacopan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 20,
      "start_date": "2025-02-21",
      "completion_date": "2027-11-27",
      "has_results": false,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-05-22T08:15:36.916Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        },
        {
          "city": "Chubbuck",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06797518"
    },
    {
      "nct_id": "NCT00967577",
      "title": "177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Cancer",
        "Head and Neck Cancer",
        "Breast Cancer",
        "Non-small Cell Lung Cancer",
        "Colorectal Cancer",
        "Pancreatic Cancer",
        "Ovarian Cancer",
        "Esophageal Cancer",
        "Gliomas"
      ],
      "interventions": [
        {
          "name": "177Lu-J591",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2009-07",
      "completion_date": "2021-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-02-02",
      "last_synced_at": "2026-05-22T08:15:36.916Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00967577"
    },
    {
      "nct_id": "NCT04557462",
      "title": "A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary IgA Nephropathy"
      ],
      "interventions": [
        {
          "name": "LNP023",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 540,
      "start_date": "2021-09-20",
      "completion_date": "2030-12-04",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-05-22T08:15:36.916Z",
      "location_count": 16,
      "location_summary": "Glendale, Arizona • San Diego, California • San Dimas, California + 13 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Dimas",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04557462"
    },
    {
      "nct_id": "NCT00356460",
      "title": "Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Renal Cell",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2006-09",
      "completion_date": "2009-05",
      "has_results": false,
      "last_update_posted_date": "2014-03-19",
      "last_synced_at": "2026-05-22T08:15:36.916Z",
      "location_count": 6,
      "location_summary": "Bethesda, Maryland • Boston, Massachusetts • Cambridge, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00356460"
    },
    {
      "nct_id": "NCT06466135",
      "title": "Study of WAL0921 in Patients With Glomerular Kidney Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Nephropathies",
        "Primary Focal Segmental Glomerulosclerosis",
        "Minimal Change Disease",
        "Primary Immunoglobulin A Nephropathy",
        "Primary Membranous Nephropathy"
      ],
      "interventions": [
        {
          "name": "WAL0921",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Walden Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 96,
      "start_date": "2024-07-02",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-05-22T08:15:36.916Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Denver, Colorado • Tamarac, Florida + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Hinsdale",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06466135"
    }
  ]
}